Call (925) 677-5041

Dr. Jewel Johl

Dr-Jewel-Johl-Urologist - CopyI practice with compassion and respect while aggressively treating your disease state. Together we discuss all medical options for your treatment plan, weighing all pros and cons, and then selecting the best approach for your lifestyle and your individual needs. I view our relationship as a long term partnership with the ultimate goal of achieving the best possible clinical outcome utilizing the most up-to-date, scientific data available. I encourage my patients to practice healthy living with appropriate nutrition and to embrace complimentary therapies that can make an emotional difference in your well-being.


Meet Dr. Johl


Dr. Jewel Johl graduated with a B.S. degree in Biochemistry from University of California at Davis and received his M.D. from Loyola University in Chicago, Illinois. He completed his internship and residency in Internal Medicine, as well as his fellowship in Hematology and Medical Oncology at University of California, Davis Medical Center in Sacramento. He is the principal/secondary author of numerous original manuscripts and publications.

Dr. Johl speaks frequently to the local medical community on cancer related topics and is an investigator participating in research and clinical trials for the Bay Area Cancer Research Group at the California Cancer and Research Institute.Dr. Johl has been in private practice since 2005 and is a partner at Diablo Valley Oncology / Hematology Medical Group located at the California Cancer and Research Institute in Pleasant Hill which specializes in comprehensive, cutting edge treatment of all forms of cancer and blood disorders.

Certifications:

Board certified in Internal Medicine and Medical Oncology and Hematology

Facility Privileges:

John Muir Medical Center Walnut Creek & Concord Campuses, San Ramon Regional Medical Center, and Sutter Delta and Sutter Solano Medical Centers

Expertise:

Dr. Johl specializes in general oncology and hematology with a special interest in gastrointestinal cancers, colorectal cancers and benign and malignant hematologic diseases.